Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2000 November;48(11) > Minerva Cardioangiologica 2000 November;48(11):341-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

ORIGINAL ARTICLES  


Minerva Cardioangiologica 2000 November;48(11):341-8

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English, Italian

Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha)

Podestà A., Carmagnini E., Parodi E., Dottori V., Crivellari R., Barberis L., Audo A., Lijoi A., Passerone G.


PDF  


Background. This study evaluates the real effectiveness of epoetin-a associated with ferrous sulphate, in reducing blood transfusion in patients undergoing elective open heart surgery not treated with autologous donation.
Methods. Sixty patients had been divided into 2 groups: group A (30 patients) treated with 525 mg ferrous sulphate three time a day per os for 3 weeks; group B (30 patients) treated with epoetin-a 10,000 UI twice a week and 525 mg ferrous sulphate 3 times a day. Grouping of patients has been randomized. In both groups hemoglobin, hematocrit, reticulocytes, iron values, ferritine, transferrine, and serological values, have been evaluated sequentially before treatment, before surgery, day of operation, 1st, 2nd, 3rd, 7th postoperative days and at discharge.
Results. In group A 86% patients needed blood transfusion (26 out of 30); in group B only 3% of patients needed blood transfusion (1 patient). One year follow up didn't show side effects related to epoetin-a.
Conclusions. This study confirms the real effectiveness of epoetin-a in reducing the postoperative need for homologous blood transfusion. No side effects due to epoetin-a treatment have been proved. The conclusion is drawn that epoetin-a can be used as an alternative to bood transfusion or in association with predeposit and in the treatment of basal anemia.

top of page

Publication History

Cite this article as

Corresponding author e-mail